

Oncology - Breast Cancer Enrollment Form (S-Z)



PATIENT INFORMATION

Patient Name: _____ Phone: (____) - ____ - _____
 Date of Birth: ____ / ____ / ____ Male Female Email: _____
 SSN: ____ - ____ - ____ Preferred method of contact: Phone Email
 Address: _____ Height: _____ in Weight: _____ lb Date: ____ / ____ / ____
 City: _____ State: _____ Zip: _____ Allergies: _____ Medications: _____ (Please attach additional pages if necessary)

PRESCRIPTION BENEFITS INFORMATION (Please attach front and back of insurance card)

Plan name: _____ ID#: _____ Group #: _____ RxBIN: _____ RxPCN: _____

PRESCRIBER INFORMATION

Prescriber Name: _____ Phone: (____) - ____ - _____ Fax: (____) - ____ - _____
 Address: _____ License #: _____
 City: _____ State: _____ Zip: _____ NPI #: _____
 Contact: _____ Clinic/Hospital Affiliation: _____ Medicaid Provider #: _____

CLINICAL CONSIDERATIONS

ICD10: _____
 Diagnosis: _____
 Mutation(s): HER2: Positive Negative
 ER: Positive Negative
 PR: Positive Negative

Past Medical History: _____
 History of therapies tried/failed and reason for discontinuation (please include dates): _____

Immunization History
 Influenza
 Date: ____ / ____ / ____

Rx

Medication	Directions	Quantity	Refills
<input type="checkbox"/> Tykerb® (lapatinib)	<input type="checkbox"/> Take 1,250 mg by mouth once daily at least one hour before or after a meal <input type="checkbox"/> Take 1,500 mg by mouth once daily at least one hour before or after a meal <input type="checkbox"/> Other: _____	<input type="checkbox"/> 105 x 250 mg tablets <input type="checkbox"/> 180 x 250 mg tablets <input type="checkbox"/> _____	
<input type="checkbox"/> Xeloda® (capecitabine)	<input type="checkbox"/> Take _____ mg (_____ mg/m ² /dose x _____ m ²) by mouth twice daily (every 12 hours) within 30 minutes after a meal on days 1-14 of a 21-day cycle	<input type="checkbox"/> _____ x 150 mg tablets <input type="checkbox"/> _____ x 500 mg tablets	
<input type="checkbox"/> Femara® (letrozole)	<input type="checkbox"/> Take 2.5 mg by mouth once daily	<input type="checkbox"/> _____ x 2.5 mg tablets	
<input type="checkbox"/> Xeloda® (capecitabine)	<input type="checkbox"/> Take _____ mg (_____ mg/m ² /dose x _____ m ²) by mouth twice daily (every 12 hours) within 30 minutes after a meal on days 1-14 of a 21-day cycle <input type="checkbox"/> Other: _____	<input type="checkbox"/> _____ x 150 mg tablets <input type="checkbox"/> _____ x 500 mg tablets	

Endocrine Therapy Options

Medication	Directions	Quantity	Refills
<input type="checkbox"/> Evista® (raloxifene)	<input type="checkbox"/> Take 60 mg by mouth once daily	<input type="checkbox"/> 30 x 60 mg tablets	
<input type="checkbox"/> Fareston® (toremifene)	<input type="checkbox"/> Take 60 mg by mouth once daily	<input type="checkbox"/> 30 x 60 mg tablets	
<input type="checkbox"/> Tamoxifen	<input type="checkbox"/> Take 20 mg by mouth once daily <input type="checkbox"/> Other: _____	<input type="checkbox"/> _____ x 20 mg tablets <input type="checkbox"/> _____ x 10 mg tablets	
<input type="checkbox"/> Arimidex® (anastrozole)	<input type="checkbox"/> Take 1 mg by mouth once daily	<input type="checkbox"/> 30 x 1 mg tablets	
<input type="checkbox"/> Aromasin® (exemestane)	<input type="checkbox"/> Take 25 mg by mouth once daily <input type="checkbox"/> Other: _____	<input type="checkbox"/> 30 x 25 mg tablets <input type="checkbox"/> _____	
<input type="checkbox"/> Femara® (letrozole)	<input type="checkbox"/> Take 2.5 mg by mouth once daily	<input type="checkbox"/> 30 x 2.5 mg tablets	
<input type="checkbox"/> Faslodex® (fulvestrant)	<input type="checkbox"/> Initial: Inject 500 mg (250 mg/5 mL into each buttock) intramuscularly slowly over 1-2 minutes on days 1, 15, and 29, then maintenance dose <input type="checkbox"/> Maintenance: Inject 500 mg (250 mg/5 mL into each buttock) intramuscularly slowly over 1-2 minutes once monthly <input type="checkbox"/> Other: _____	<input type="checkbox"/> _____ x 250 mg/5 mL prefilled syringes (supplied in packages of 2 injections)	

By signing below, I authorize the pharmacy and its representatives to act as an agent to initiate and execute the insurance prior authorization process. I also certify that the above therapy is medically necessary and that the information above is accurate to the best of my knowledge.

Prescriber's Signature: _____ MD DO PA CRNP Date: ____ / ____ / ____

NO STAMPS

In order for a brand name product to be dispensed, the prescriber must handwrite "Brand Necessary" or "Brand Medically Necessary" on the prescription.

SHIPPING INFORMATION

Ship to: Patient Physician/Clinic Date Shipment Needed By: ____ / ____ / ____



PHONE: 855-726-8479 (412-246-9858)

FAX: 855-246-3986 (412-787-9400)

www.pantherxrare.com

© PANTHERx Rare, LLC. All rights in the product names of all third-party products appearing in this document, whether or not appearing with the trademark symbol, belong exclusively to their respective owners.